Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 14/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | ACHE | P22303 | 4/20 | 0.64 |
| ▸ | BCHE | P06276 | 3/20 | 0.64 |
| ▸ | MAOA | P21397 | 3/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190950 | 0.89 | APP (0.77) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL4382277 | 0.89 | APP (0.77) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL28924931 | 0.88 | APP (0.84) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL14190936 | 0.85 | APP (0.79) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL4380573 | 0.85 | APP (0.79) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL4376030 | 0.84 | APP (0.74) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL4381093 | 0.84 | APP (0.79) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL14190919 | 0.84 | APP (0.74) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL14190926 | 0.84 | APP (0.79) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL2830260 | 0.83 | APP (0.82) | APPKDM4EMEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | APP 892/4885KDM4E 1567/4885MEN1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.